Nonetheless, patients should be instructed to report any signs orsymptoms of hepatic dysfunction (e.g., jaundice). Long-term therapy with intramuscular testosterone enanthate hasproduced multiple hepatic adenomas. Due to lack of controlled studies in women and potentialvirilizing effects, Natesto is not indicated for use in women. It would be appropriate tore-evaluate the hematocrit 3 to 6 months after starting testosterone treatment,and then annually. Advise patients to report any nasal symptoms orsigns to their health care professional. Gynecomastia may develop and may persist in patientsbeing treated with androgens, including Natesto, for hypogonadism.seeADVERSE REACTIONS. The concurrent use of testosterone with corticosteroids may result in increased fluid retention and requires monitoring particularly in patients with cardiac, renal, or hepatic disease. Changes in anticoagulant activity may be seen with androgens, therefore more frequent monitoring of international normalized ration (INR) and prothrombin time is recommended in patients taking warfarin, especially at the initiation and termination of androgen therapy. In women, testosterone can produce hirsutism (excessive facial/body hair growth), deepening of the voice, and other signs of virilization. Some female athletes may have naturally higher levels of testosterone than others, and may be asked to consent to sex verification and either surgery or drugs to decrease testosterone levels. Anabolic–androgenic steroids (AAS), including testosterone and its esters, have also been taken to enhance muscle development, strength, or endurance. Alternatively, testosterone products for women are available from compounding pharmacies in the United States, although such products are unregulated and manufacturing quality is not ensured. There are approved testosterone products for women in Australia, where it is considered a drug of dependence, medicines that are subject to misuse and trafficking, and some European countries. There are no testosterone products approved for use in women in the United States and many other countries. In accordance, men experience sexual dysfunction at testosterone levels of below 300 ng/dL, and men that have levels of testosterone of approximately 200 ng/dL frequently experience such problems. Unlike testosterone ester and ether prodrugs however, these prohormones are only weakly androgenic/anabolic. However, estradiol exerts negative feedback on the hypothalamic–pituitary–gonadal axis and, for this reason, prevention of its formation can reduce this feedback and disinhibit gonadal production of testosterone, which in turn can increase levels of endogenous testosterone. However, these drugs do this via prevention of the conversion of testosterone into its more potent metabolite dihydrotestosterone (DHT), and this results in dramatically reduced circulating levels of DHT (which circulates at much lower relative concentrations). 5α-Reductase inhibitors like finasteride and dutasteride can slightly increase circulating levels of testosterone by inhibiting its metabolism. Natesto (testosterone) is commonly used to treat low testosterone levels in men caused by certain conditions, such as hypogonadism. Common side effects include nasal symptoms (such as runny nose, nosebleeds, or nose discomfort), headache, and changes in certain lab test results. Eligible commercially insured patients may pay as low as $0 copay on each valid Natesto prescription or refill up to a maximum of $3500 in assistance annually. Patients who are enrolled in any federal healthcare program, including, without limitation, Medicare Part D, Medicare Advantage, FFS Medicaid, Managed Medicaid, Veterans Administration, Champus, TriCare, and Indian Health Service, are not eligible to participate in the Natesto Savings Program. The Natesto Savings Program is valid ONLY for patients with private (commercial) insurance. Withdrawal symptoms can be experienced upon abrupt discontinuation in patients with addiction. Regular monitoring of serum calcium concentrations is recommended in these patients.
